Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01683994
Title Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

prostate cancer


Cabozantinib + Docetaxel

Age Groups: adult
Covered Countries USA

No variant requirements are available.